Two weeks before the midterm election, the Trump administration announced a sweeping plan to subject physician-administered drugs in Medicare Part B to foreign price controls. The ANPR “demonstration project” would subject half of the country to the mandatory pricing scheme but will ripple through the entire Medicare program.
Chief editor, Rob Wright, discusses some forward-looking sessions from the annual CNS Summit, along with what to expect in Life Science Leader’s annual outlook issue.
ISR looked at each month in the past year to identify the biggest expansion news announced by large CDMOs.
The fate of your business rests largely on the willingness of individuals to choose to invest their best discretionary effort in your company’s cause — to dig deep for innovative ideas, to imagine solutions outside any box, to perceive subtle shifts and faint signals.
See the answer from Anu Hans, VP of strategic initiatives at Janssen Supply Chain.
Helen Torley, president and CEO of Halozyme Therapeutics, on hyaluronan and the role it plays in development of ENHANZE, PEGPH20, along with a staining diagnostic to determine patients with high levels of hyaluronic acid (HA).
Halozyme Therapeutics’ president and CEO, Dr. Helen Torley, discusses her approach to preparing and presenting as a first-time CEO at the annual J.P. Morgan Healthcare Conference.
Seven biopharmaceutical industry thought leaders weigh in on technology, tax cuts, and the political landscape to help you get ready for the coming year.